TABLE 1.

Rv1168c can potentially be used to diagnose smear-positive and smear-negative pulmonary as well as extrapulmonary TB cases^a

Antigen	Total extrapulmonary TB cases (n = 32)		Total pulmonary TB cases (n = 77)		Smear-positive pulmonary TB cases (n = 53)		Smear-negative pulmonary TB cases (n = 24)
	Mean ± SD	% Responders	Mean ± SD	% Responders	Mean ± SD	% Responders	Mean ± SD	% Responders
Rv1168c	1.15 ± 0.38	81.3	1.01 ± 0.38	73.0	1.01 ± 0.36	71.6	1.03 ± 0.42	75.0
ESAT-6	0.62 ± 0.22	21.9	0.61 ± 0.28	37.6	0.60 ± 0.26	34.0	0.64 ± 0.32	45.8
Hsp60	0.52 ± 0.22	16.0	0.59 ± 0.23	27.2	0.61 ± 0.22	28.3	0.56 ± 0.24	25.0
PPD	0.41 ± 0.17	12.5	0.42 ± 0.19	14.3	0.40 ± 0.16	9.4	0.46 ± 0.23	21.0

^aThe data from Fig. 2A were replotted to compare the antibody responses of the pulmonary and extrapulmonary TB patients against Rv1168c versus ESAT-6, Hsp60, and PPD. The percentage of responders showing absorbance values greater than or equal to the cutoff value (mean OD₄₉₂ plus 6 SD, based on results with BCG-vaccinated control sera) was compared for pulmonary and extrapulmonary TB groups. The pulmonary TB cases were further categorized as smear positive and smear negative, and responders to Rv1168c were compared with those for ESAT-6, Hsp60, and PPD by calculating the percentage of individuals showing absorbance values greater than or equal to the mean OD₄₉₂ plus 6 SD (obtained with BCG-vaccinated control sera).